Status: Active Trial | Marker: RET
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)
Patients with a locally advanced or metastatic solid tumor with RET activation
To provide access to selpercatinib for patients with locally advanced or metastatic solid tumors with activating RET alterations (and other evidence of RET activation) who are 18 years of age or older.
In- and exclusion Criteria
1. Patients with a locally advanced or metastatic solid tumor with RET activation who are not eligible for an ongoing selpercatinib clinical trial (e.g., for clinical, geographic or financial reasons or due to cohort closure)
2. Patients for whom, in the opinion of the Investigator, there is no comparable or satisfactory alternative authorized medicinal product available to treat the patient’s solid tumor with RET activation
Loxo Oncology, Inc.
281 Tresser Boulevard, 9th Floor
Stamford CT 06901
University Hospital of Cologne
Dep. I of Internal Medicine
Phone: +49 221 478 87008
Fax: +49 221 478 87010
Prof. Dr. Jürgen Wolf
Letzte Änderung: 1. October 2020